GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya

As GlaxoSmithKline looks to deepen its cancer R&D, it's penned an oncology development program with Ideaya Biosciences.

South San Francisco-based Ideaya broke cover in 2016 with a $46 million series A round that set it up to run synthetic lethality screens. That entails using genome editing tools to identify pairs of mutations that, when hit simultaneously, lead to cell death.